narcolepsy medications
... such as imipramine, clomipramine and protryptilene were found decades ago to be helpful in reducing episodes of cataplexy. In recent years, Xyrem and newer generation antidepressants have largely replaced the older tricyclics as the preferred treatments for the REM-related symptoms of narcolepsy. On ...
... such as imipramine, clomipramine and protryptilene were found decades ago to be helpful in reducing episodes of cataplexy. In recent years, Xyrem and newer generation antidepressants have largely replaced the older tricyclics as the preferred treatments for the REM-related symptoms of narcolepsy. On ...
Yale scientists explain how ketamine vanquishes depression within
... Ketamine, used as an anesthetic in human and veterinary medicine, has emerged in the past few years as a promising, rapid-acting antidepressant. When administered intravenously at low doses, it can lift symptoms of deep depression within hours, for seven to 10 days. Typical antidepressants, which ac ...
... Ketamine, used as an anesthetic in human and veterinary medicine, has emerged in the past few years as a promising, rapid-acting antidepressant. When administered intravenously at low doses, it can lift symptoms of deep depression within hours, for seven to 10 days. Typical antidepressants, which ac ...
(PSD) July 2015 PBAC Meeting
... continual survival) and was not supported by the evidence, as the longest follow-up in the study was at 29 days of treatment, with only two out of the 58 patients having been observed beyond three years of age; there were many confounding factors with the evidence, including varying doses of carglum ...
... continual survival) and was not supported by the evidence, as the longest follow-up in the study was at 29 days of treatment, with only two out of the 58 patients having been observed beyond three years of age; there were many confounding factors with the evidence, including varying doses of carglum ...
Medications for Glaucoma
... If you are taking more than one drug, even if it is over-the-counter or herbal, be sure to check with a doctor or pharmacist about drug interactions. Plan ahead for refills so you don’t run out. Check the expiration date. Let your doctor know if you take any other medications or supplements. This in ...
... If you are taking more than one drug, even if it is over-the-counter or herbal, be sure to check with a doctor or pharmacist about drug interactions. Plan ahead for refills so you don’t run out. Check the expiration date. Let your doctor know if you take any other medications or supplements. This in ...
Pharmaceutical Dosage Forms
... – particular pharmaceutical product containing active and inactive pharmaceutical ingredients formulated into the particular dosage form. – Packed and labelled appropriately – Two major types of PP according the origin: • Manufactured in large scales by pharmaceutical industry (original and generic ...
... – particular pharmaceutical product containing active and inactive pharmaceutical ingredients formulated into the particular dosage form. – Packed and labelled appropriately – Two major types of PP according the origin: • Manufactured in large scales by pharmaceutical industry (original and generic ...
guidelines for writing proposals and consent forms
... of time following the trial that they should continue with birth control. A pregnancy test before entering the study will be necessary and possibly repeated during the study. Similar warnings may be required for male subjects for they or their partner to use effective birth control during the study ...
... of time following the trial that they should continue with birth control. A pregnancy test before entering the study will be necessary and possibly repeated during the study. Similar warnings may be required for male subjects for they or their partner to use effective birth control during the study ...
DOES NEW MEAN BETTER
... Q: What side effects should we watch for with the new agents?1 Current data suggests the PDE5 inhibitors are similar in terms of the severity and frequency of side effects. Most commonly reported side effects in clinical trials were headache, facial flushing, nasal congestion and dyspepsia. Sildenaf ...
... Q: What side effects should we watch for with the new agents?1 Current data suggests the PDE5 inhibitors are similar in terms of the severity and frequency of side effects. Most commonly reported side effects in clinical trials were headache, facial flushing, nasal congestion and dyspepsia. Sildenaf ...
Lopinavir/low dose ritonavir - WHO archives
... ‘causal pathway’ between viral infection and disease outcomes, but more directly in the case of viral measures. The viral end-point has come to be regarded as superior to a measure as a prognostic marker, although results have not been entirely consistent. A meta-analysis of trials of 2 NRTIs (plus ...
... ‘causal pathway’ between viral infection and disease outcomes, but more directly in the case of viral measures. The viral end-point has come to be regarded as superior to a measure as a prognostic marker, although results have not been entirely consistent. A meta-analysis of trials of 2 NRTIs (plus ...
Pharmacokinetics of Chemotherapeutic Agents in Kidney Disease
... of the parent drug (58). For patients with CKD receiving HDAC, Kintzel recommends for CrCl of 46–60 mL/min, give 60% of the dose; for CrCl of 31–45 mL/min, give 50% of the dose; and for CrCl of ,30 mL/min, do not administer (4). Smith developed a dosing algorithm for HDAC based on daily serum creati ...
... of the parent drug (58). For patients with CKD receiving HDAC, Kintzel recommends for CrCl of 46–60 mL/min, give 60% of the dose; for CrCl of 31–45 mL/min, give 50% of the dose; and for CrCl of ,30 mL/min, do not administer (4). Smith developed a dosing algorithm for HDAC based on daily serum creati ...
Cardiac Considerations During MMT
... An important question is whether methadone doses significantly higher than those typically used in many MMT programs might carry greater cardiac risks. In the Krantz et al. TdP cases (2002), doses ranged from 65 to 1000 mg/d, with most greater than 200 mg/d (average 397 mg/d). Similarly, the dose ra ...
... An important question is whether methadone doses significantly higher than those typically used in many MMT programs might carry greater cardiac risks. In the Krantz et al. TdP cases (2002), doses ranged from 65 to 1000 mg/d, with most greater than 200 mg/d (average 397 mg/d). Similarly, the dose ra ...
RSPT 1410 Common Respiratory Drugs
... • this action is associated with a decrease in the size of the DNA in the sputum • the change in sputum viscosity is dose dependent – greater reduction occurs at higher concentrations of the drug ...
... • this action is associated with a decrease in the size of the DNA in the sputum • the change in sputum viscosity is dose dependent – greater reduction occurs at higher concentrations of the drug ...
Cardiac Considerations During Methadone Therapy
... An important question is whether methadone doses significantly higher than those typically used in many MMT programs might carry greater cardiac risks. In the Krantz et al. TdP cases (2002), doses ranged from 65 to 1000 mg/d, with most greater than 200 mg/d (average 397 mg/d). Similarly, the dose ra ...
... An important question is whether methadone doses significantly higher than those typically used in many MMT programs might carry greater cardiac risks. In the Krantz et al. TdP cases (2002), doses ranged from 65 to 1000 mg/d, with most greater than 200 mg/d (average 397 mg/d). Similarly, the dose ra ...
IDWeek 2015_Dalbavancin Poster #786_Van Anglen et al
... (53%) received other intravenous antibiotics (IVABs) prior to treatment with DAL for a median of 5 days. Eighty seven pts (83%) received 2 doses of DAL, one week apart. Six pts (6%) received more than 2 doses. Infusions were administered by peripheral intravenous catheter in 84 pts (80%). Among 81 p ...
... (53%) received other intravenous antibiotics (IVABs) prior to treatment with DAL for a median of 5 days. Eighty seven pts (83%) received 2 doses of DAL, one week apart. Six pts (6%) received more than 2 doses. Infusions were administered by peripheral intravenous catheter in 84 pts (80%). Among 81 p ...
sw_qa_402-3_final_version
... along with 10% of the parent drug (6,7,11). M6G is a potent analgesic and CNS depressant (11). It may cause prolonged clinical effects as the half-life increases from 2.1 hours in normal renal function to up to 27 hours in ESRF (2). Moreover, M6G crosses the blood brain barrier and slowly re-equilib ...
... along with 10% of the parent drug (6,7,11). M6G is a potent analgesic and CNS depressant (11). It may cause prolonged clinical effects as the half-life increases from 2.1 hours in normal renal function to up to 27 hours in ESRF (2). Moreover, M6G crosses the blood brain barrier and slowly re-equilib ...
Drugs for primary generalized epilepsy
... none are currently used as the first treatment for epilepsy. Felbamate was approved by the FDA in early 1994 and was the first new drug for epilepsy to be approved in 15 years. Although there was great initial enthusiasm for this agent, in less than a year post-marketing surveillance revealed an una ...
... none are currently used as the first treatment for epilepsy. Felbamate was approved by the FDA in early 1994 and was the first new drug for epilepsy to be approved in 15 years. Although there was great initial enthusiasm for this agent, in less than a year post-marketing surveillance revealed an una ...
Bevacizumab in the treatment of kras wild type metastatic
... FOLFOX every 2 weeks: Oxaliplatin: 85 mg/m2 on day 1 of each cycle; Leucovirin: 200 mg/m2 on day 1 and 2 of each cycle; Fluorouracil Bolus: 400 mg/m2 on day 1 and 2 of each cycle; Florouracil IV: 600 mg/m2 on day 1 and 2 of each cycle // FOLFIRI every 2 weeks: Irinotecan: 180 mg/m2 on day 1 of each ...
... FOLFOX every 2 weeks: Oxaliplatin: 85 mg/m2 on day 1 of each cycle; Leucovirin: 200 mg/m2 on day 1 and 2 of each cycle; Fluorouracil Bolus: 400 mg/m2 on day 1 and 2 of each cycle; Florouracil IV: 600 mg/m2 on day 1 and 2 of each cycle // FOLFIRI every 2 weeks: Irinotecan: 180 mg/m2 on day 1 of each ...
To Rip - Akorn Pharmaceuticals
... colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution. Carcinogenesis, Mutagenesis, Impairment of Fertility There are no known human data on long-term potential for carcinogenicity, m ...
... colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution. Carcinogenesis, Mutagenesis, Impairment of Fertility There are no known human data on long-term potential for carcinogenicity, m ...
Luvox and Luvox CR (fluvoxamine)
... can be administered as a single dose at bedtime. Seniors and people with severe and chronic illness may require lower dosages (50–100 mg/day) than the average person. In treating children (ages 8–17 years) with OCD, the recommended starting dose is 25 mg administered as a single bedtime dose. The do ...
... can be administered as a single dose at bedtime. Seniors and people with severe and chronic illness may require lower dosages (50–100 mg/day) than the average person. In treating children (ages 8–17 years) with OCD, the recommended starting dose is 25 mg administered as a single bedtime dose. The do ...
LYRICA® Hard Capsule 75mg, 150mg, 300mg
... LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related. Administer the total daily dose in two or three divided doses. In ...
... LYRICA at doses of 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. Both the efficacy and adverse event profiles of LYRICA have been shown to be dose-related. Administer the total daily dose in two or three divided doses. In ...
pediatric handbook
... AMINOGLYCOSIDES GN Aerobes (including Pseudomonas aeruginosa) Tobramycin IV: 5-6 mg/kg/dose q24h (extended frequency dosing is preferred in patients without renal impairment to maximize pharmacokinetics and dynamics of drug) Synergy with beta-lactams for severe S. aureus and Enterococcus infections: ...
... AMINOGLYCOSIDES GN Aerobes (including Pseudomonas aeruginosa) Tobramycin IV: 5-6 mg/kg/dose q24h (extended frequency dosing is preferred in patients without renal impairment to maximize pharmacokinetics and dynamics of drug) Synergy with beta-lactams for severe S. aureus and Enterococcus infections: ...
[Product Monograph Template
... * The splitting of VASOTEC® tablets is not advised. Each tablet is made with 2.5, 5, 10 or 20 mg of enalapril maleate that appears as 2, 4, 8 or 16 mg of enalapril sodium in the tablets. ...
... * The splitting of VASOTEC® tablets is not advised. Each tablet is made with 2.5, 5, 10 or 20 mg of enalapril maleate that appears as 2, 4, 8 or 16 mg of enalapril sodium in the tablets. ...
Management of clozapine-resistant schizophrenia
... 2001). The therapeutic effects of lamotrigine augmentation were also assessed in a rigorous randomised placebo-controlled cross-over study of 34 clozapine-resistant patients (Tiihonen et al, 2003). In this 14-week study, lamotrigine treatment significantly improved positive symptoms and general psyc ...
... 2001). The therapeutic effects of lamotrigine augmentation were also assessed in a rigorous randomised placebo-controlled cross-over study of 34 clozapine-resistant patients (Tiihonen et al, 2003). In this 14-week study, lamotrigine treatment significantly improved positive symptoms and general psyc ...
Dopa-responsive Dystonia in Children
... Parkinson disease, of therapy [4•]. Untreated individuals with DRD develop diurnal fluctuations with marked improvement in the morning and worsening in the evening. This is not a constant feature, and it is more apparent in adolescents and young adults than in younger children. Untreated individuals ...
... Parkinson disease, of therapy [4•]. Untreated individuals with DRD develop diurnal fluctuations with marked improvement in the morning and worsening in the evening. This is not a constant feature, and it is more apparent in adolescents and young adults than in younger children. Untreated individuals ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.